Key Stats for AMGN Stock
- Past week’s performance: 8.5%
- 52-week range: $270 to $418
- Valuation model target price: $461
- Implied upside: 12.3% over 2.4 years
See how Amgen’s growth-driver portfolio shapes its own price target with TIKR’s Guided Valuation Model (It’s free) >>>
Growing Through Patent Cliffs: Inside Amgen’s Beat and Raise
Amgen (AMGN) climbed to a record high after posting a Q2 that topped expectations on every major metric. Revenue rose 10% to $10.1 billion, while adjusted earnings per share reached $6.29, well ahead of the $5.60 consensus estimate. Free cash flow surged to $3.5 billion, giving the company added flexibility for manufacturing investment and shareholder returns.
The breadth of the beat stood out most. Twenty-two products delivered double-digit sales growth, and Amgen’s six named growth drivers, which include Repatha, Evenity, Tezspire, rare-disease treatments, oncology drugs, and biosimilars, grew 26% and now generate nearly 70% of product sales. That shift matters because it shows Amgen’s growth is becoming less dependent on any single blockbuster drug.
Management responded by raising full-year guidance twice over. Amgen now expects 2026 revenue between $38.2 billion and $39.4 billion, up from its prior range, along with adjusted earnings per share of $22.30 to $23.50. Biosimilars grew 29% during the quarter, with newer entrant Pavblu up 121%, helping offset a 33% decline in Prolia and Xgeva sales as biosimilar competitors continue launching against those older drugs.
CEO Robert Bradway said the results “demonstrate our ability to grow through patent expirations and increased competition.” He pointed to the breadth of Amgen’s pipeline, including late-stage trials for obesity candidate MariTide, as reasons for confidence heading into the back half of the year. Going forward, the key test is whether newer drugs can keep outrunning the steady erosion in Amgen’s older, biosimilar-exposed franchise.
See analysts’ growth forecasts and price targets for AMGN (It’s free) >>>
A Steady Compounder, Not a Bargain
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue Growth (CAGR): 3.7%
- Operating Margins: 44.1%
- Exit P/E Multiple: 16.5x
Based on these inputs, the model estimates a target price of $461, implying a 12.3% total return and an annualized return of 4.9% over the next 2.4 years.
Amgen’s valuation model reflects a mature, cash-generative business rather than a high-growth story. A 3.7% revenue growth assumption sits below the company’s own five-year average near 7.6%, reflecting how biosimilar competition on Prolia and Xgeva is expected to weigh on the top line even as newer drugs expand. The 44.1% operating margin assumption stays close to Amgen’s historical range, showing profitability isn’t the concern here.
The 16.5x exit multiple exceeds Amgen’s 10-year average near 14.1x, crediting its improving mix of higher-margin, faster-growing products. With a 4.9% annualized return, the stock sits below the 5% caution threshold, favoring income and stability over deep value.
What could change that calculus is pipeline execution. Late-stage data on MariTide, Amgen’s obesity candidate, and its Lp(a) cardiovascular program could meaningfully shift growth assumptions if either reads out positively over the next year or two.
Compared to peers, Amgen’s dividend yield near 2.5% and payout ratio above 60% also appeal to income-focused investors who care less about the model’s modest annualized return and more about steady cash distribution.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Amgen vs. the Biopharma Field
Merck (MRK) offers one of the clearer comparisons, since both companies are managing patent-related declines on older franchises while investing in newer therapeutic areas. Merck’s recently approved oral cholesterol drug now competes directly against parts of Amgen’s cardiovascular portfolio, adding a new competitive wrinkle just as Amgen leans harder on Repatha for growth.
AbbVie (ABBV) represents another relevant comparison given its own experience navigating the loss of Humira exclusivity in recent years. AbbVie’s newer immunology drugs have grown fast enough to offset that decline, a playbook Amgen is now attempting with its own six key growth drivers replacing Prolia and Xgeva as the primary growth engine.
Amgen’s 16.5x model multiple trails faster-growing biotech peers, reflecting its more moderate revenue outlook. However, its roughly 44% operating margin exceeds many peers funding unprofitable pipeline programs. Amgen’s advantage lies in converting its commercial portfolio into steady cash flow rather than pursuing maximum growth.
What’s Driving AMGN Stock Going Forward?
The most immediate catalyst is continued execution on Amgen’s six named growth drivers, which need to keep growing near 26% to offset ongoing declines in Prolia and Xgeva. Any deceleration in that growth rate would pressure the broader thesis that Amgen has successfully diversified beyond its aging franchises.
Regulatory developments around Tavneos remain an overhang worth tracking. Amgen has submitted new data challenging the FDA’s proposal to withdraw the drug from the market, and the outcome could affect both revenue and the company’s broader regulatory standing in Europe, where a similar review is underway.
Pipeline catalysts also loom large. Investors are watching competitor Lp(a) cardiovascular trial data, which management says could provide directional insight into Amgen’s Olpasiran program. Continued MariTide progress also remains crucial, as it represents Amgen’s most important obesity opportunity.
Finally, capital allocation remains a steady tailwind. Amgen raised its dividend 6% during the quarter and continues investing in domestic manufacturing capacity, signaling confidence in free cash flow generation even as the company navigates biosimilar competition on its legacy products.
Build your own Amgen return scenario using TIKR’s Guided Valuation Model (Free) >>>
Should You Invest in Amgen?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AMGN, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AMGN alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze AMGN stock on TIKR Free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
